When to use JAKAVI® (ruxolitinib)
Show more →
Prescribing JAKAVI® (ruxolitinib) for MF
Show more →
JAKAVI® (ruxolitinib) safety profile
Show more →
Optimising JAKAVI® (ruxolitinib) dosing
Show more →



  1. Summary of Product Characteristics Jakavi®, most up to date version at www.medicines.ie.
  2. Verstovsek S, et al. N Engl J Med. 2012;366:799-807.
  3. Harrison C, et al. N Engl J Med. 2012;366:787-789.
  4. Verstovsek S et al. Longterm treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. 2017; 10(1): 55.
  5. Verstovsek S et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol. 2017; 10(1): 156.
172184 | November 2021

Prescribing Information


Click here for Product Information

Reporting of side effects
Adverse events (side effects) can be reported via the HPRA. Reporting forms and information can be found at https://www.hpra.ie/homepage/about-us/report-an-issue. Adverse events could also be reported to Novartis preferably via www.report.novartis.com or by email: [email protected] or by calling (01) 2080 612. For information on any of our medicinal products please contact Medical Information on (01) 260 1255.


Ask Speakers


Medical Information Request